Amol Akhade: Sacituzumab govitecan is withdrawn from Metastatic urothelial cancer
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on X:
“So after 3 years of accelerated approval based upon phase 2 data , sacituzumab govitecan is withdrawn from Metastatic urothelial cancer as tropics 04 study did not show OS benifit.
So one option less, after ev plus pembrolizumab in metastatic urothelial cancer.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023